20 Jun 2013
Platform to be deployed in multi-center, 2,000-eye cataract treatment clinical study.
OptiMedica, Sunnyvale, CA, USA, has been awarded a tender for five Catalys Precision Laser Systems for use in a French multi-center randomized clinical study sponsored by University Hospital of Bordeaux, France.
Mark Forchette, CEO at OptiMedica, commented, “We thank the French research coordinators for choosing Catalys for this important study.
"We are confident that patients and surgeons will benefit from the performance that Catalys has been shown to deliver, and we look forward to working closely with each center.”
"This research study is an important initiative that will allow us to investigate the best way to deliver the procedure for the benefit of the patient, surgeon and healthcare system in the future.”
Catalys is a precision laser cataract surgery platform that delivers gentle, highly customized procedures with best-in-class accuracy and performance. OptiMedica says Catalys is the only laser platform designed specifically for laser cataract surgery, and it offers several benefits for surgeons and patients.
Key proprietary features of the system include a Liquid Optics Interface that ensures gentle docking with minimal intraocular pressure rise and clear optics for unsurpassed imaging and laser delivery; and Integral Guidance, 3D Full Volume Optical Coherence Tomography (OCT) and automated surface mapping algorithms that guide laser delivery.
Background to Catalys
At the end of 2011, optics.org reported on OptiMedica's receiving 510(k) market clearance from the US Food and Drug Administration (FDA) enabling its Catalys laser system to be used for cataract surgery.
About the Author
Matthew Peach is a contributing editor to optics.org.